Conducting a clinical trial during the pandemic? Here’s what you need to know from the FDA’s updated guidance.

The US FDA today issued updated guidance to assist sponsors in assuring the safety of trial participants, maintaining compliance with good clinical practice (GCP), and minimizing risks to trial integrity for the duration of the COVID-19 public health emergency.

The guide goes further within an appendix explaining general considerations by providing answers to questions that the Agency has received about conducting clinical trials during the COVID-19 pandemic.

Available to download directly from the FDA here: https://lnkd.in/eqtXVKi the guidance is non-binding and provides recommendations rather than law, with the objective of ensuring the continued safety of trial participants. Sponsors are encouraged to consider each circumstance, focusing on the potential impact on the safety of trial participants, and modify each study conduct accordingly.

It’s clear that choosing a pharma partner who is alert, aware, professional, and fluid enough to adjust to the unpredictable daily developments is paramount. Contact us today to discuss your clinical testing needs or to find out more.

Additional News

  • 9 July 2025

    HER-096: A possible breakthrough in Parkinson’s disease treatment

    This testimonial highlights our collaboration with Herantis Pharma on the analytical development and nonclinical support for HER-096, a promising candidate in the fight against Parkinson’s disease.

  • 9 June 2025

    Ensuring Success in Buccal Film Development: The Midazolam Film Case Study

    Fast, Simple, Effective: Unlocking the Potential of Midazolam Films

  • 15 May 2025

    From Analytical Similarity to Clinical Data: Tailoring Evidence for Biosimilar Approval

    On behalf of Conscio Group, we are pleased to invite you to the upcoming free educational webinar.